title: A retrospective analysis of lung metastasis in 64 patients with alveolar soft part sarcoma.
abstract: OBJECTIVE
  To analyse the lung metastasis and possible factors influencing lung metastasis in alveolar soft part sarcoma (ASPS) patients.
  
  
  METHODS
  The medical records of 64 consecutive ASPS patients were reviewed to analyse their treatments, features of lung metastasis, and possible factors influencing lung metastasis.
  
  
  RESULTS
  Thirty-six females and 28 males with a median age of 27 years were included. The primary disease sites were the extremities in 51 patients and other locations in 13 patients. The median primary tumour size was 5 cm. Wide local excision of the primary tumour was performed on 56 patients (87.5 %). Thirteen patients (20.3 %) received postoperative adjuvant radiotherapy, and nine patients (14.1 %) underwent adjuvant chemotherapy. Twelve patients (18.8 %) presented with metastatic lung disease. Twenty-nine patients (45.3 %) developed metastatic lung disease during follow-up. Lung metastasis occurred in 64.1 % of the patients. Lung metastasis was detected at a median interval of 20 months after primary ASPS diagnosis. Being male, >20 years of age, having a primary tumour size ≥ 5 cm, and local recurrence were associated with a greater rate of lung metastasis. Median survival after the diagnosis of lung metastasis was 34 months. The 5-year survival rates were 64.1 and 95.2 % for patients with and without lung metastasis (P < 0.001). Thirty-seven patients with metastatic lung disease received anthracycline- and ifosfamide-based chemotherapy. One patient experienced a partial remission.
  
  
  CONCLUSIONS
  ASPS patients have a high prevalence of lung metastasis. Sex, age, primary tumour size, and local recurrence are major factors influencing lung metastasis. Chemotherapy is not efficacious in ASPS patients with lung metastasis.
authors.affiliation: Department of Radiation Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, People's Republic of China.
authors.forename: Y-P
authors.initials: YP
authors.lastname: Liu
authors.affiliation: Department of Radiation Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, People's Republic of China.
authors.forename: J
authors.initials: J
authors.lastname: Jin
authors.affiliation: Department of Radiation Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, People's Republic of China.
authors.forename: W-H
authors.initials: WH
authors.lastname: Wang
authors.affiliation: Department of Radiation Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, People's Republic of China.
authors.forename: S-L
authors.initials: SL
authors.lastname: Wang
authors.affiliation: Department of Radiation Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, People's Republic of China.
authors.forename: Y-W
authors.initials: YW
authors.lastname: Song
authors.affiliation: Department of Radiation Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, People's Republic of China.
authors.forename: H
authors.initials: H
authors.lastname: Fang
authors.affiliation: Department of Radiation Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, People's Republic of China.
authors.forename: H
authors.initials: H
authors.lastname: Ren
authors.affiliation: Department of Radiation Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, People's Republic of China.
authors.forename: X-F
authors.initials: XF
authors.lastname: Liu
authors.affiliation: Department of Radiation Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, People's Republic of China.
authors.forename: Z-H
authors.initials: ZH
authors.lastname: Yu
authors.affiliation: Department of Radiation Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, People's Republic of China. yexiong12@163.com.
authors.forename: Y-X
authors.initials: YX
authors.lastname: Li
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D018943:Anthracyclines / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D002648:Child; D015331:Cohort Studies; D005121:Extremities / Q000473:pathology / Q000601:surgery*; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000556:secondary / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D012307:Risk Factors; D018234:Sarcoma, Alveolar Soft Part / Q000556:secondary / Q000628:therapy*; D012737:Sex Factors; D012983:Soft Tissue Neoplasms / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate; D055815:Young Adult
chemical_list: D018943:Anthracyclines; D007069:Ifosfamide
keywords: Alveolar soft part sarcoma; Chemotherapy; Correlative factor; Lung metastasis